At the European Society for Medical Oncology (ESMO) 2025 event, held in Berlin, Germany, between 17-21 October, Celcuity ...
HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action —— Lead ...
Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. The current PI3K 3C inhibitors in use in ...
ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies ...
Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. There are several clinical trials that are ...
First investigational drug candidate using the HUTCHMED ATTC technology platform to create potent targeted therapy payloads while mitigating ...
Monday, Relay Therapeutics Inc. RLAY shared interim data for RLY-2608 from the ReDiscover study of RLY-2608 alone, in combination with fulvestrant, and in combination with fulvestrant and ribociclib ...
There are quite a pipeline of development, including multiple companies invested in this PI3K inhibitor development and -- but with very few success. And the first generation and second generation ...
Celcuity expects to complete a rolling NDA submission for gedatolisib under the FDA RTOR program by Q4 2025. Click here to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback